Hubbry Logo
Ana AslanAna AslanMain
Open search
Ana Aslan
Community hub
Ana Aslan
logo
17 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Ana Aslan
Ana Aslan
Ana Aslan
View on Wikipedia
from Wikipedia

Ana Aslan (Romanian pronunciation: [ˈana asˈlan]; 1 January 1897 – 20 May 1988), born Anna Aslanyan, was a Romanian biologist and physician of partial Armenian descent. She was born in Brăila and died in Bucharest. Aslan was a specialist in gerontology, academician from 1974 and the director of the National Institute of Geriatrics and Gerontology (1958–1988) known for her invention of the drug Gerovital (H3). Aslan received international recognition for her research in gerontology.

Key Information

Early life

[edit]

Ana was the youngest of four children, two brothers and two sisters, born to Mkrtitch and Sofia Aslanyans. Ana was said to be a very intellectual child, learning to read and write already by age four. At the age of 13, her father died, and her family then moved to Bucharest, Romania. It was in Bucharest where she began her studies. She graduated from the Central School of Bucharest in 1915. The premature death of her father, whom she was close to, was said to be the reason she wanted to become a physician. Although the medical field was not a desirable field for women to enter, Ana Aslan decided that was the path she wanted to pursue and attended the Faculty of Medicine from 1915 to 1922. Her mother did not support this decision of becoming a physician because of financial strains, so Ana Aslan went on a hunger strike until her mother accepted her medical career. During her time in undergraduate studies, she attended to soldiers as a nurse during the First World War.

Research

[edit]

After graduating from the Faculty of Medicine in 1922, she began working with Daniel Danielopolu who supervised her doctoral thesis. She obtained her M.D. degree in cardiovascular physiology in 1924. Her focus was on physiology and the process of ageing. While experimenting on the effects that procaine had on arthritis, Aslan discovered other beneficial effects of this drug. It was this discovery that led to a three-year study and eventual invention of her drug called Gerovital (H3), which she prescribed for the effects of aging. With hesitation from fellow scientists that Gerovital was a "fountain of youth", Aslan kicked off a research study to prove the results. Over a period of two years, blood samples were taken from 15,000 people, with some of them receiving Gerovital and some receiving a placebo. 40% of the people who took Gerovital had less sick-leave days, and mortality rate from the flu epidemic was 13% in placebo patients while only being 2.7% in patients who took the drug. In 1976, with a pharmacist named Elena Polovrăgeanu, they invented another drug named Aslavital, which was a similar drug to Gerovital aimed to delay the skin aging process.[citation needed]

Awards

[edit]
Aslan on a 2016 Romanian stamp
Aslan on a 1996 Romanian stamp

Ana Aslan received many distinctions for her research activity, for example:

  • Member of the International Academy of Science, Munich and first Co-President
  • "Cross of Merit" – First Class of the Order of Merit, Germany, 1971
  • "Cavalier de la Nouvelle Europe" Prize Oscar, Italy, 1973
  • "Les Palmes Academiques", France, 1974
  • "Honorary Foreign Citizen and Honorary Professor of Sciences", Philippines, 1978
  • "Member Honoris Causa" Diploma of the Bohemo-Slovakian Society of Gerontology, 1981
  • "Leon Bernard" Prize, important distinction granted by the World Health Organization upon nomination and endorsement by officials of a member state (in this case by the Romanian Nicolae Ceauşescu) for contributing to the development of gerontology and geriatrics, 1982

Cosmetic lines

[edit]

Ana Aslan patented two cosmetic products (hair lotion and cream Gerovital H3), entrusting their production to Farmec company and Miraj. The two companies have since diversified their range of cosmetics, and traditional procaine hydrochloride was eliminated from the formula.[1]

Legacy

[edit]

Ana Aslan was considered a pioneer of social medicine. Years after becoming the head of the physiology department at the Institute of Endocrinology of Bucharest, she founded the Institute of Geriatrics of Bucharest. Ana Aslan, in 1959 organized the Romanian Society of Gerontology and Geriatrics.[2] The Romanian Society of Gerontology was the first in the world to channel its research into clinic, experimental, and social researches, devise a therapeutic strategy to prevent the process of aging, and organize a national health network for the prevention of aging. Her drug was used by many famous politicians and celebrities around the world, including John F. Kennedy.[citation needed]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Ana Aslan

View on Grokipedia
from Grokipedia
Ana Aslan (January 1, 1897 – May 20, 1988) was a pioneering Romanian physician and gerontologist renowned for founding the world's first Institute of Geriatrics in in 1952 and for developing Gerovital H3, a procaine-based treatment promoted for its purported anti-aging effects. Born in to an Armenian family, Aslan graduated from the University of Bucharest's Faculty of Medicine in 1924 with a focus on , later specializing in . She advanced to professor of at the University of Timișoara in 1945 and head of the physiology department at Bucharest's Institute of in 1949, before founding the Institute of , which she directed from 1958 until her death, becoming the National Institute of and Gerontology in 1974. Aslan's most notable contribution was her research on procaine hydrochloride, initiated in the late 1940s, which led to the formulation of Gerovital H3 in 1956—a 2% solution combined with , , and —intended to prevent and reverse aging processes. She claimed the treatment improved memory, mobility, skin tone, and overall vitality in elderly patients, based on a three-year prospective study and long-term observations of over 189 subjects, reporting benefits such as reduced and hair repigmentation. Convinced that "aging was a disease that could be prevented," Aslan extended her work to Aslavital in 1970 and the concept of gerontoprophylaxis in 1976, emphasizing preventive . She also founded the Romanian Society of Gerontology and Geriatrics in 1959 and launched a quarterly journal to advance the field internationally. Aslan's therapies gained global attention, attracting high-profile patients including , , , and , who sought her treatments in . Her innovations earned her the World Health Organization's Leon Bernard Prize in 1982 for contributions to , and she was posthumously honored with a Romanian postage stamp in 1996. However, Gerovital H3 faced significant scientific scrutiny; a 1977 U.S. National Institute on Aging review found insufficient evidence for anti-aging claims beyond mild monoamine oxidase inhibition, and a 2008 Cochrane Review concluded no benefits for or . The U.S. banned its import for anti-aging purposes in 1982, citing lack of proven efficacy and safety. Despite controversies, Aslan's emphasis on proactive aging research influenced modern .

Early Life and Education

Childhood and Family

Ana Aslan, originally named Anna Aslanyan, was born on January 1, 1897, in , , a bustling city on the , to parents of Armenian descent, Mărgărit and Sofia Aslan (née Popovici). As the youngest of four children—her siblings included Bombonel, Sergiu, and Angela—she grew up in an intellectually vibrant household shaped by her family's partial Armenian heritage. Her father, a grain merchant with a passion for literature and science, fostered an environment of cultured discussions on art, politics, and intellectual pursuits, while her mother, twenty years his junior and multilingual, emphasized resilience and elegance. This cosmopolitan upbringing in instilled in young Ana a precocious curiosity; by age four, she was reading and writing fluently in French, and she often engaged in adult conversations that highlighted her serious demeanor. The family's Armenian roots contributed to a heritage of intellectual achievement, with relatives like Garabet and I.C. Aslan exemplifying contributions to and , influencing her early . Tragedy struck when Ana was 13, as her father succumbed to at age 72, exacerbated by his gambling and poor investments that had already eroded the family's wealth. This loss prompted the sale of their home and relocation to , where the family faced significant financial hardships and a precarious material situation. Drawing on her mother's instilled fighting spirit, Ana demonstrated remarkable personal resilience amid the poverty, channeling her early fascination with science—sparked by familial dialogues—into a determination that later propelled her toward medical studies as a means to overcome adversity.

Medical Training and Early Influences

Ana Aslan graduated from the Central School of in 1915, overcoming significant family opposition to women's higher education by staging a to assert her determination to pursue a medical career. In October 1915, at the age of 18, she enrolled in the Faculty of Medicine at the . She completed her undergraduate studies in 1922 and obtained her M.D. degree in 1924 with magna cum laude honors and a focus on , where she defended her doctoral thesis on vasomotor innervation in humans under the guidance of Daniel Danielopolu. During this period, from 1916 to 1919, Aslan served as a nurse in military hospitals in , providing care to wounded soldiers and gaining hands-on experience in clinical settings that reinforced her commitment to medicine. Following her graduation, Aslan worked as an internist in hospitals from 1922 to 1925, where her exposure to patients with conditions, including those related to aging, began to shape her lifelong interest in and age-related diseases. These early clinical experiences highlighted the physiological impacts of aging, motivating her to explore preventive approaches in later work.

Professional Career

Initial Medical Practice

After graduating from the Faculty of Medicine and Pharmacy of the in 1924 with a doctoral thesis on , Ana Aslan commenced her professional career as a preparator under Daniel Danielopolu at II in , where she conducted postgraduate research on regulation and . Her foundational training in equipped her to address complex endocrine and cardiovascular disorders in clinical settings. During the interwar period, Aslan advanced to the role of lector from 1936 to 1946, treating patients across medical facilities with a specialization in and . In this capacity, she frequently managed elderly individuals suffering from chronic conditions, observing recurring patterns of age-related physiological decline, such as diminished function, which informed her evolving clinical insights. She also contributed to efforts by co-founding the Society for Neurovegetative and becoming a founding member of the Hospitals Society, promoting advancements in and amid Romania's interwar challenges. In the 1940s, Aslan extended her practice during Romania's involvement in and the subsequent transition, serving as a of at the Faculty of Medicine in from 1945 to 1949, where she oversaw clinical training and patient care in a resource-strained environment. Her experiences with elderly patients exhibiting cardiovascular complications during this era highlighted limitations in curative treatments, prompting a gradual shift toward preventive strategies for age-associated decline by the late 1940s. This orientation was evident in her 1949 appointment as head of the department at Bucharest's Institute of , where she began integrating observations from cases into broader approaches for mitigating aging effects.

Founding and Leadership of the Geriatrics Institute

In 1952, Ana Aslan founded the world's first Institute of Geriatrics in Bucharest, Romania, under the auspices of the Romanian Ministry of Health through a decision of the Ministerial Cabinet. This pioneering institution was established to address the growing societal need for specialized care and research on aging, incorporating clinical, biological, and endocrinological units to conduct comprehensive studies on geriatric health. Aslan's vision transformed geriatrics from a marginal field into a structured medical discipline, drawing on her earlier observations in endocrinology to emphasize preventive and holistic approaches to age-related conditions. Aslan served as director of the institute from its inception in 1952 until her death in 1988, providing steadfast leadership over 36 years and overseeing its expansion into a national center for gerontological research and treatment. Under her guidance, the facility grew to include advanced clinical trials and patient care programs, treating thousands of individuals while fostering interdisciplinary collaboration among biologists, endocrinologists, and clinicians. In 1959, Aslan expanded the institute's influence by organizing the Romanian Society of Gerontology and Geriatrics, which promoted national standards in the field and facilitated knowledge dissemination through a dedicated quarterly journal. During Romania's communist era, Aslan navigated significant administrative challenges, including resource limitations and political favoritism that prioritized access for high-ranking officials over ordinary citizens. Despite the country's international isolation under the Ceaușescu regime, she cultivated vital global collaborations, attracting dignitaries such as , , and for treatments, and earning recognition from the , which in 1964 proposed the institute as a model for geriatric care worldwide. These efforts not only sustained the institute's operations but also elevated Romania's profile in global amid geopolitical constraints.

Scientific Research

Development of Gerovital H3

In the late , Ana Aslan began investigating the effects of , initially known as a local anesthetic, beyond its traditional uses, observing its potential to influence cellular metabolism and overall vitality in aging individuals. Between 1946 and 1956, her studies revealed procaine's beneficial actions on cellular functions, including enhanced oxygen utilization and metabolic normalization, which laid the groundwork for its application in . By 1956, Aslan formulated Gerovital H3 as a stabilized 2% hydrochloride solution, incorporating 0.12% and 0.10% to prevent rapid and extend its therapeutic duration, with the mixture adjusted to a of 3.3 for optimal stability. This preparation was administered primarily via , aimed at promoting by targeting age-related physiological decline. The additives ensured slower absorption and prolonged activity compared to plain , allowing for biweekly dosing regimens in clinical settings. Aslan proposed that Gerovital H3's efficacy stemmed from its reversible inhibition of (MAO), an enzyme that degrades s such as serotonin and , thereby preventing age-associated depletion and . In her publications, including detailed accounts in the Journal of the American Geriatrics Society, she elaborated on this mechanism as central to the drug's prophylaxis against aging, linking MAO inhibition to improved neural function, reduced free radical damage, and enhanced cellular energy production. These claims were supported by and showing dose-dependent MAO suppression in and liver tissues, positioning Gerovital H3 as a modulator of biochemical aging processes. However, the anti-aging benefits of Gerovital H3 have been subject to significant scientific debate, with reviews finding insufficient evidence beyond mild MAO inhibition effects.

Additional Studies on Aging and Procaine

In the and , Ana Aslan expanded her research on beyond its initial applications, conducting clinical studies that demonstrated its potential to enhance metabolic processes in elderly patients. These investigations, involving cohorts of over 1,000 participants, reported improvements in memory recall, overall vitality, and management of chronic conditions such as and cardiovascular issues, attributed to 's role in optimizing oxygen utilization and cellular permeability. Aslan's theoretical framework positioned aging as a reversible characterized by diminished cellular energy production and accumulation, which she argued could be addressed through 's biochemical actions. In her publications in the Romanian Journal of Gerontology and during the 1970s, she detailed how restores mitochondrial function and inhibits , thereby revitalizing energy metabolism at the cellular level and counteracting age-related decline. This perspective built on her foundational work with Gerovital H3, emphasizing 's broader utility in prophylaxis against metabolic imbalances. In 1980, co-invented Aslavital, a topical -based formulation designed to combat aging by preserving integrity and enhancing dermal elasticity through localized metabolic stimulation. The product combined 2% hydrochloride with vitamins and plant extracts, targeting age-induced degradation in clinical applications. International trials of therapies in the and extended to high-profile participants, yielding anecdotal reports of enhanced longevity and vitality. Celebrities such as and reportedly experienced prolonged physical and cognitive resilience following treatments at Aslan's institute, with de Gaulle crediting for supporting his health into advanced age. These cases, while not rigorously controlled, contributed to global interest in procaine's geroprotective potential.

Recognition and Awards

National Honors in Romania

Ana Aslan's pioneering work in and earned her significant recognition within , beginning with her election to the Academy of Medical Sciences in 1936, where she was acknowledged for her early contributions to and . This honor positioned her as a key figure in the Romanian medical establishment, reflecting her growing influence in advancing specialized fields like and aging studies. During the communist era, received several state honors for her role in promoting and scientific progress, particularly in addressing aging populations through prophylactic treatments. In 1967, she was awarded the Scientific Merit Class I for her innovative approaches to geriatric care. This was followed by the Order of Sanitary Merit Class I on April 8, 1970, bestowed for exceptional merits in the field of protection. Her in establishing geriatric protocols that integrated principles further underscored these distinctions, emphasizing preventive care for elderly citizens as a national priority. In 1971, Aslan attained one of Romania's highest accolades, the title of Hero of Socialist Labor, accompanied by the gold medal "," awarded on May 4 for outstanding contributions to science and societal well-being. This recognition highlighted her impact on national health initiatives, including the widespread application of her procaine-based therapies to improve in aging demographics. Later, in 1974, she was elected a full member of the , affirming her status as a leading intellectual in the country. That same year, the Geriatrics Institute she had directed since 1958 was elevated to the National Institute of Gerontology and and officially named in her honor, symbolizing her foundational role in Romanian . Aslan continued to receive honors into the 1980s, culminating in the Order of Labor Class I on May 7, 1981, for her dedication to the Romanian Communist Party's health policies and her enduring advancements in for the elderly. These national distinctions collectively celebrated her efforts to institutionalize as a vital component of Romania's framework.

International Acclaim and Memberships

Ana Aslan's contributions to earned her significant international recognition, culminating in the award of the World Health Organization's Léon Foundation Prize and Medal in 1982 for her advancements in the field. This prestigious honor, named after the former WHO assistant director-general, highlighted her innovative approaches to aging research and was presented to her as one of the few recipients from . Beyond this accolade, Aslan received the Cross of Merit, First Class of the from in 1971, acknowledging her pioneering work in geriatric . She garnered similar honors from numerous countries, having lectured in 57 nations worldwide, which amplified her global influence in the scientific community. Aslan held memberships in 81 international scientific bodies, reflecting the breadth of her professional esteem. Notable among these were her election to the New York Academy of Sciences and her affiliation with the International Association of Gerontology, where she contributed to key discussions on aging processes. Her worldwide reputation was further enhanced by treating prominent figures, including Indian Prime Minister , who sought her therapies for vitality and . Such high-profile consultations underscored Aslan's status as a leading authority in anti-aging interventions, drawing international attention to her clinical expertise.

Commercial Ventures

Cosmetic and Therapeutic Product Lines

In the 1960s, Ana Aslan extended her research on -based formulations into by patenting Gerovital H3-based products designed to combat aging effects on and . She secured a for a hair lotion in 1967, which incorporated Gerovital H3 to prevent , reduce , and promote scalp health through its stabilizing effects on cellular processes associated with aging. A corresponding skin cream was also patented during this period, targeting wrinkles and skin vitality by leveraging the same anti-aging principles derived from her studies. To commercialize these innovations, Aslan formed production partnerships with Romanian companies Farmec and , granting them rights to manufacture and distribute the formulations. Farmec, a longstanding cosmetics producer, began creating Gerovital H3-inspired lotions, shampoos, and creams focused on hydration, wrinkle reduction, and skin firming for mature users. similarly contributed to the lineup, emphasizing topical applications that extended the brand's reach in . These collaborations resulted in accessible consumer products that applied Aslan's gerontological insights to daily skincare routines. Beyond cosmetics, Aslan's work led to therapeutic extensions of Gerovital H3, including oral tablets and injectable ampoules marketed across and internationally for enhancing vitality and slowing age-related decline. These forms, administered in clinical settings or as supplements, gained popularity in countries like , , and the during the 1970s for their purported regenerative benefits. In response to international regulatory pressures in the , particularly following restrictions on as a drug ingredient, cosmetic variants of Gerovital H3 were reformulated to exclude while retaining inspired active components like antioxidants and emollients. This adjustment allowed continued production and sales of shampoos, lotions, and creams compliant with cosmetic standards, preserving the brand's focus on anti-aging without the original pharmaceutical element.

Patents and Commercial Impact

Ana Aslan secured key patents for her inventions in during the , with H3 receiving approval for production in 1957 and subsequent international patents in over 30 countries covering its injectable and oral formulations for geriatric applications. These patents extended to topical uses, such as a 1970 Romanian patent for a hair treatment lotion incorporating procaine hydrochloride, , and ascorbic acid. In 1976, Aslan, collaborating with Elena Polovrăgeanu, obtained a Romanian inventor's for Aslavital, a procaine-based derivative aimed at therapies, which was later patented internationally in dozens of countries and industrially produced from 1980 onward. The commercialization of H3 and Aslavital drove significant economic activity through exports to over 30 countries starting in 1958, with production handled by entities like Sicomed in for pharmaceuticals and Farmec in Cluj for cosmetics derived from the formulas. These exports, alongside services, generated approximately 18 million U.S. dollars in annual revenue for the Romanian state by the 1970s, funding further research at the Geriatrics Institute. H3 alone accounted for about 60% of Farmec's turnover, underscoring its role in bolstering Romania's pharmaceutical sector. Aslan's institute played a pivotal role in Romanian medical tourism during the 1970s and 1980s, attracting foreign patients—estimated at 5–10% of total tourists between 1975 and 1989—for Gerovital H3 treatments, which enhanced the country's international reputation and contributed to economic inflows. However, the U.S. Food and Drug Administration's 1982 import prohibition under automatic detention alert (effective via Import Alert 61-01) classified Gerovital H3 as an unapproved new drug, curtailing its entry into the lucrative American market and thereby limiting global sales potential.

Legacy and Controversies

Enduring Influence on

Following Ana Aslan's death in , the National Institute of and in was renamed in her honor in 1992 and has continued operating as a pioneering European center for geriatric care and research. The institute, which she founded in 1952 as the world's first dedicated facility of its kind, now provides multidisciplinary services across three locations, serving approximately 20,000 patients annually with a staff of around 500 professionals focused on preventing chronic age-related diseases and promoting active (as of 2025). It remains a key hub for integrated geriatric treatment, emphasizing functional assessments and recovery programs that build on Aslan's foundational principles. Aslan's research on procaine-based therapies, particularly Gerovital H3, has sustained influence through ongoing investigations into its geroprotective mechanisms, including recent studies exploring its applications in age-related conditions like rheumatic diseases and pain management in the elderly. These efforts, often conducted in Romanian clinical settings, continue to reference her early observations on procaine's role in modulating cellular and autonomic nervous system regulation, contributing to contemporary discussions on anti-aging interventions. Aslan pioneered the social dimensions of by advocating for preventive approaches, culminating in her 1976 formulation of gerontoprophylaxis—a framework treating aging as a preventable process through early interventions and modifications. In , her leadership of the Romanian Society for Gerontology and Geriatrics from 1959 until her death influenced national policies on , promoting integrated medical-social services to enhance for older adults. Internationally, as a member of the International Association of Gerontology's Executive Bureau, she advanced global standards for preventive , advocating for policies that prioritize healthy aging and reduce institutionalization through community-based support systems. In education, Aslan's legacy endures through the training programs at her institute, which have prepared generations of physicians in geriatric , fostering expertise in anti-aging therapies and holistic elderly care. Her extensive lecture tours across 57 countries disseminated these principles, shaping curricula in worldwide and inspiring the integration of preventive strategies into medical training programs.

Scientific Debates and Criticisms

Western scientists in the 1970s and 1980s expressed significant skepticism toward Ana Aslan's Gerovital H3, often labeling it as pseudoscience due to the absence of rigorous double-blind, placebo-controlled trials supporting its anti-aging claims. The National Institute on Aging's review during this period concluded that available studies were methodologically flawed, with any reported benefits likely attributable to placebo effects rather than genuine geroprotective actions. This criticism highlighted the reliance on anecdotal evidence and open-label observations from Aslan's clinic, which failed to meet contemporary standards for clinical validation. In 1982, the U.S. (FDA) imposed a ban on importing Gerovital H3, classifying it as an unapproved new drug with no proven benefits for anti-aging or age-related conditions. The decision followed a comprehensive evaluation by the National Institute on Aging, which found controlled studies demonstrating only placebo-level effects on cognitive function, mood, or , alongside potential risks such as . Subsequent analyses reinforced these findings, noting that while might exhibit mild properties, it lacked substantiation for broader effects. Ongoing debates about procaine's geroprotective potential persist, as evidenced by a systematic review that acknowledged preliminary and mechanisms in cellular models but emphasized insufficient evidence from human trials to support claims of extension. The review underscored methodological limitations in earlier animal studies, such as those conducted by , and called for more robust, randomized controlled trials to resolve these uncertainties, while cautioning against unsubstantiated therapeutic promotion. Ethical concerns arose from the heavy reliance on celebrity endorsements and the high costs of treatments at Aslan's , which drew international figures like despite the lack of scientific validation, raising questions about exploitation of vulnerable affluent patients seeking unproven therapies. In contrast, during her lifetime, Aslan enjoyed strong institutional support in , where the government endorsed Gerovital H3 and established the National Institute of and under her direction, reflecting national pride in her work amid international dismissal.

References

  1. https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2963390-9/fulltext
  2. https://youth.europa.eu/nnfe/ana-aslan_en
  3. https://muzeulfemeilorremarcabile.ro/en/stories/ana-aslan/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8349289/
  5. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.12278
  6. https://www.fundatiaanaaslan.ro/books/inmemoriam.pdf
  7. https://acad.ro/institutia/ACADEMICA/2024/nr06/06_art07.pdf
  8. https://www.medlife.ro/articole-medicale/ana-aslan-ce-rol-a-avut-in-revolutionarea-medicinei
  9. https://ancaroxanaconstantin.ro/ana-aslan-a-romanian-legend-and-her-miracle-treatment/
  10. https://reference.jrank.org/biography-2/Aslan_Ana.html
  11. https://adevarul.ro/stiri-locale/calarasi/povestea-fascinanta-a-anei-aslan-medicul-care-a-1842162.html
  12. https://www.aosr.ro/wp-content/uploads/2018/11/Romanian-Personalities-EN.pdf
  13. https://www.mayoclinicproceedings.org/article/S0025-6196(11)63390-9/fulltext
  14. https://afostodata.ro/poveste-angleza-ana-aslan/
  15. https://unibuc.ro/ana-aslan-absolventa-a-universitatii-din-bucuresti-omagiata-de-comisia-nationala-a-romaniei-pentru-unesco-la-50-de-ani-de-la-intrarea-in-academia-romana/?lang=en
  16. https://www.contur.ro/ENG/gerovital/otopeni.html
  17. https://business-review.eu/news/the-legendary-ana-aslan-institute-the-business-story-of-its-rejuvenation-167775
  18. https://www.nytimes.com/1963/12/01/archives/use-of-procaine-in-aged-retested-results-found-positive-further.html
  19. https://rjgg.ro/pdf/1980_v1.1p5.pdf
  20. https://www.romania-insider.com/famous-romanians-ana-aslan-founder-of-the-worlds-first-geriatrics-institute
  21. https://www.researchgate.net/publication/353622559_Procaine-The_Controversial_Geroprotector_Candidate_New_Insights_Regarding_Its_Molecular_and_Cellular_Effects
  22. https://lege5.ro/Gratuit/gu4timrv/decretul-nr-200-1970-privind-conferirea-ordinului-si-medaliei-meritul-sanitar-unor-cadre-medico-sanitare
  23. https://lege5.ro/Gratuit/gu4tqnrr/decretul-nr-155-1971-privind-conferirea-titlului-de-erou-al-muncii-socialiste
  24. https://publicnewsfm.ro/2024/05/18/19-mai-1952-s-a-infiintat-institutul-de-geriatrie-devenit-din-1974-institutul-national-de-gerontologie-si-geriatrie-ana-aslan/
  25. https://apps.who.int/gb/awards/pdf_files/Bernard/Winners_en.pdf
  26. http://breaktime.erasmus.istitutocasanova.edu.it/wp-content/uploads/sites/2/2023/07/Ana-Aslan.pdf
  27. https://www.chicagotribune.com/1988/05/29/dr-ana-aslan-said-her-drug-renewed-youth/
  28. https://patents.google.com/patent/DE1617633A1/en
  29. https://www.researchgate.net/publication/273449933_Intellectual_Property_as_a_Drive_for_Sustainable_Medical_Tourism_--_The_Ana_Aslan_case
  30. https://www.farmec.ro/compania/en/the-farmec-story/
  31. https://quackwatch.org/related/gerovital/
  32. https://www.accessdata.fda.gov/cms_ia/industry_66.html
  33. https://ana-aslan.ro/
  34. https://www.developmentaid.org/organizations/view/425084/ana-aslan-institute-of-gerontology-and-geriatrics
  35. https://www.preprints.org/manuscript/202410.1533
  36. http://www.worldrecordacademy.org/records/medical/world-s-first-geriatrics-institute-ana-aslan-institute-of-gerontology-and-geriatrics-218216
  37. https://www.mdpi.com/2071-1050/16/5/1827
  38. https://unesdoc.unesco.org/ark:/48223/pf0000050910
  39. https://www.researchgate.net/publication/239732760_The_Reappearance_of_Procaine_Hydrochloride_Gerovital_H3_for_Antiaging
Add your contribution
Related Hubs
User Avatar
No comments yet.